A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
暂无分享，去创建一个
C. Chen | A. Cartmell | J. Berenson | C.-S. Chen | O. Yellin | M. Flam | Y. Nassir | R. Swift | R. Vescio | R. Vescio | J. Hilger | T. Kazamel | T. Woliver | E. Bravin | Jacqueline Hilger